Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
6.50
0.00 (0.00%)
Nov 21, 2024, 11:43 AM EST - Market open

Acrivon Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-76.98-60.39-31.17-16.24-5.31
Depreciation & Amortization
0.850.540.360.040.01
Loss (Gain) From Sale of Investments
-3.56-3.32-0.7--
Stock-Based Compensation
13.6411.622.190.50
Other Operating Activities
0.880.780.731.42.17
Change in Accounts Payable
-0.193.61-0.250.80.08
Change in Other Net Operating Assets
4.674.53-1.29-0.470.24
Operating Cash Flow
-60.68-42.64-30.12-13.98-2.8
Capital Expenditures
-3.09-1.29-2.17-0.24-0.02
Investment in Securities
-42.5652.01-139.51--
Investing Cash Flow
-45.6550.72-141.68-0.24-0.02
Long-Term Debt Issued
----0.06
Net Debt Issued (Repaid)
----0.06
Issuance of Common Stock
70.410.78104.480-
Repurchase of Common Stock
-3.17-1.3---
Other Financing Activities
52.43-1.03-2.77--
Financing Cash Flow
119.66-1.55101.71112.222.89
Net Cash Flow
13.346.52-70.08980.07
Free Cash Flow
-63.77-43.93-32.28-14.22-2.82
Free Cash Flow Per Share
-2.14-1.99-7.83-8.16-1.97
Levered Free Cash Flow
-35.79-22.33-20.03-8.79-
Unlevered Free Cash Flow
-35.79-22.33-20.03-8.79-
Change in Net Working Capital
-6.13-8.75-0-1.03-
Source: S&P Capital IQ. Standard template. Financial Sources.